Clinical Efficacy of Ginkgo Biloba Extract in the Treatment of Knee Osteoarthritis

NCT ID: NCT05398874

Last Updated: 2022-09-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-01

Study Completion Date

2022-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy and safety of the Ginkgo biloba extract in patients with Knee OA.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ginkgo + standard

the patients received Ginkgo biloba extract in addition to standard treatment

Group Type ACTIVE_COMPARATOR

Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)

Intervention Type COMBINATION_PRODUCT

120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily

placebo + standard

the patients received a placebo in addition to the standard treatment

Group Type PLACEBO_COMPARATOR

placebo in addition to the standard treatment

Intervention Type COMBINATION_PRODUCT

placebo in addition to the standard treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ginkgo biloba extract + standard treatment( paracetamol+Diclofenac100mg SR)

120 mg leaf extract , twice daily in addition to Diclofenac 100 mg Once daily + paracetamol 1g Twice daily

Intervention Type COMBINATION_PRODUCT

placebo in addition to the standard treatment

placebo in addition to the standard treatment

Intervention Type COMBINATION_PRODUCT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ginko Natrol company + Dolipran+Olfen 100 SR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients 40-75 years old with knee OA.
* Grade II and Grade III according to the Kellgrenn-Lawrence (KL) grading system of radiographic OA.

Exclusion Criteria

* Pregnancy, breastfeeding
* Liver or renal problems
* Patient taking any drug that might interact with Ginkgo extract (eg. warfarin, etc.)
* patient with cardiovascular or cerebral vascular disorders, uncontrolled diabetes, allergic to ginkgo, recent surgery or hospital admission, \>75 years old.
* Allergic or contraindicated to using NSAIDs
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kufa University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Maryam Al-Haddad

Researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Private Clinic

Najaf, N/A (Outside of US), Iraq

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iraq

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MEC-13

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effects of Aquamin F on Osteoarthritis of the Knee
NCT00452101 COMPLETED PHASE1/PHASE2